Press Enter to search · Esc to close
A new phase 3 trial shows a once-daily pill can deliver meaningful weight loss without a needle — and that small detail could change who actually gets treated.
A 26-week Phase 2 trial pits a once-daily oral non-peptide against dulaglutide — and the β-cell and insulin-sensitivity signals are hard to ignore.
A secondary analysis of a placebo-controlled trial in patients with alcohol use disorder and obesity found exenatide lowered a blood marker of drinking — but only after months, not weeks.